Clinical trial
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With…
NCT00361166 · ACADIA Pharmaceuticals Inc., Industry · Completed
Key facts
| NCT number | NCT00361166 |
|---|---|
| Title | Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone |
| Official title | A Randomized, Double Blind, Multi-Center Study to Assess the Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol or Risperidone to Schizophrenic Subjects |
| Lead sponsor | ACADIA Pharmaceuticals Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | ACP-103 |
| Enrollment | 400 |
| Start date | Aug 1, 2005 |
| Completion | Mar 1, 2007 |
| First posted | Aug 7, 2006 |
| Last update posted | Mar 22, 2007 |
| Countries | Brazil, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: